Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
摘要
默克与Moderna宣布，其个性化mRNA黑色素瘤疫苗在后期试验中较标准治疗将死亡或复发风险降低42%。两家公司正与监管机构沟通推动审批。该结果被视为黑色素瘤治疗的重要进展，也增强了人们对mRNA疫苗及个体化抗癌药物成为癌症治疗新范式的期待。Moderna首席执行官表示，试验结果印证了mRNA技术有望从根本上改变癌症治疗方式的判断。
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday.
The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved. More broadly, the vaccine's success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines offer a new paradigm for cancer therapies.
"From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor," Moderna CEO Stéphane Bancel said in a statement. The trial results "mark a defining moment for that vision and show what’s possible when we rethink how medicines are made." They also "reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer," he said.
转载信息
评论 (0)
暂无评论，来留下第一条评论吧